Xlife Sciences AG (XSWX:XLS) Accounts Payable & Accrued Expense: CHF0.34 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:XLS Xlife Sciences AG XSWX:XLS
42 GF Score
Price CHF16.00
GF Value CHF7.09
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Xlife Sciences AG Accounts Payable & Accrued Expense?

Xlife Sciences AG XSWX:XLS 42 Accounts Payable & Accrued Expense is CHF0.34 Mil as of Dec. 2025. GuruFocus rates XSWX:XLS with a GF Score™ of 42/100 and a GF Value™ of CHF7.09 (Significantly Overvalued). The stock has 10 warning signs investors should review.

Xlife Sciences AG's quarterly accounts payable & accrued expense declined from Dec. 2024 (CHF1.03 Mil) to Jun. 2025 (CHF0.92 Mil) and declined from Jun. 2025 (CHF0.92 Mil) to Dec. 2025 (CHF0.34 Mil).

Xlife Sciences AG's annual accounts payable & accrued expense increased from Dec. 2023 (CHF0.97 Mil) to Dec. 2024 (CHF1.03 Mil) but then declined from Dec. 2024 (CHF1.03 Mil) to Dec. 2025 (CHF0.34 Mil).

Xlife Sciences AG Accounts Payable & Accrued Expense Historical Data

* Premium members only.

The historical data trend for Xlife Sciences AG's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xlife Sciences AG Accounts Payable & Accrued Expense Chart

Xlife Sciences AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable & Accrued Expense
Get a 7-Day Free Trial 0.38 0.63 0.97 1.03 0.34

Xlife Sciences AG Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Accounts Payable & Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.97 0.83 1.03 0.92 0.34
XSWX:XLS
42GF Score
Xlife Sciences AG XSWX:XLS
Accounts Payable & Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xlife Sciences AG Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

What does a Accounts Payable & Accrued Expense of CHF0.34 Mil mean?
Xlife Sciences AG (XSWX:XLS) has a Accounts Payable & Accrued Expense of CHF0.34 Mil as of Dec. 2025. Accounts payable and accrued expenses are amounts a company expects to pay to suppliers and others. View historical data on Xlife Sciences AG and its competitors.
Is Xlife Sciences AG's Accounts Payable & Accrued Expense too high?
Xlife Sciences AG's current Accounts Payable & Accrued Expense is CHF0.34 Mil. Overall, Xlife Sciences AG has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xlife Sciences AG's Accounts Payable & Accrued Expense compare to VRTX and REGN?
Xlife Sciences AG's Accounts Payable & Accrued Expense of CHF0.34 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable & Accrued Expense for a Biotechnology company?
A good Accounts Payable & Accrued Expense depends on the Biotechnology industry context. However, Accounts Payable & Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable & Accrued Expense mean?
A high Accounts Payable & Accrued Expense can signal that a stock is expensive relative to its fundamentals. Accounts payable and accrued expenses are amounts a company expects to pay to suppliers and others. View historical data on Xlife Sciences AG and its competitors. Xlife Sciences AG's current Accounts Payable & Accrued Expense is CHF0.34 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xlife Sciences AG stock overvalued right now?
Based on GuruFocus' analysis, Xlife Sciences AG (XSWX:XLS) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF7.09, compared to a current price of CHF16.00 — trading 125.7% above its estimated fair value. The current Accounts Payable & Accrued Expense is CHF0.34 Mil. Xlife Sciences AG's overall GF Score™ is 42/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable & Accrued Expense calculated?
Accounts Payable & Accrued Expense is calculated from a company's financial statements. For Xlife Sciences AG (XSWX:XLS), the current Accounts Payable & Accrued Expense is CHF0.34 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xlife Sciences AG (XSWX:XLS) Overvalued in 2026?

Based on GuruFocus' analysis, Xlife Sciences AG stock appears to be overvalued. The current stock price of CHF16.00 is trading 125.7% above its estimated GF Value™ of CHF7.09. GuruFocus considers Xlife Sciences AG to be Significantly Overvalued.

Key valuation signals for XSWX:XLS:

  • Accounts Payable & Accrued Expense: CHF0.34 Mil
  • GF Value™: CHF7.09 vs. price of CHF16.00 (125.7% above fair value)
  • GF Score™: 42/100 with 10 warning signs

No single metric tells the full story. See the XSWX:XLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xlife Sciences AG Business Description

Other Exchanges XLSz:UKXLS:Germany
Address Talacker 35, Zurich, CHE, 8001
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
42GF Score

Get the complete analysis for XSWX:XLS

Accounts Payable & Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF16.00
Price
CHF7.09
GF Value